South Korea’s Celltrion Inc. announced on Thursday that it will supply three treatments, including its blood cancer drug Truxima (rituximab) to Peru.
Celltrion's Truxima secured an order in tenders conducted by both the Peruvian Ministry of Health (CENARES) and Peru Social Health Insurance (EsSalud).
It will be supplied to CENARES in two installments (500mg) and to EsSalud for a year (100mg), capturing over half of the overall Peruvian market for this drug, encompassing both biosimilar and original versions.
These wins grant Celltrion a dominant 53% share of the Peruvian Trastuzumab market and a solid 20% share of the adalimumab market.
Celltrion plans to launch two additional biosimilars in Peru later this year: Remsima SC (subcutaneous injection for autoimmune diseases) in mid-2024 and Vegzelma (for colorectal and non-small cell lung cancer) by year-end.
We use cookies to provide the best user experience. By continuing to browse this website, you will be considered to accept cookies. Please review our Privacy Policy to learn our cookie policy.